has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens recombinant vector vaccine subcutaneous route therapeutic vaccine function vaccine in clinical trial role recombinant vector vaccine role recombinant viral vector vaccine therapeutic cancer vaccine TriAd cancer vaccine Gene name: brachyury Hayleigh Kahn NCT: https://clinicaltrials.gov/study/NCT04247282 1048 Gene name: CEA VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6359 4582 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035 Gene name: MUC1 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034 6862 NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373 A cancer vaccine of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded. ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded. The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment. cancer vaccine 6359 Jie Zheng